<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660396</url>
  </required_header>
  <id_info>
    <org_study_id>MOVE-HF</org_study_id>
    <nct_id>NCT04660396</nct_id>
  </id_info>
  <brief_title>Monitoring Outpatient Blood VolumE in Heart Failure</brief_title>
  <acronym>MOVE-HF</acronym>
  <official_title>Monitoring Outpatient Blood VolumE in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daxor Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Daxor Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients discharged following heart failure treatment, the consistency of blood volume&#xD;
      status and components over time is unknown. The primary objective is to describe the rate of&#xD;
      change, if any, of the plasma volume and red blood cell volume following hospitalization and&#xD;
      discharge of patients with heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over 6 million Americans suffer from heart failure, one of the most prevalent and deadly&#xD;
      diseases. High 30-day readmission and mortality rates have persisted despite advances in&#xD;
      care. Clinical guidelines suggest blood volume assessment and clinical management to&#xD;
      euvolemia or normal blood volume, but standard methods of blood volume diagnosis have been&#xD;
      shown to be unreliable. FDA-cleared Blood volume analysis (BVA) has been used to quantify&#xD;
      otherwise undiagnosed blood volume derangements in heart failure and other indications. Also,&#xD;
      care guided by BVA has been demonstrated to improve inpatient heart failure readmission and&#xD;
      mortality. A similar analysis has not previously been performed immediately following&#xD;
      hospital discharge, though this period is understood to be challenging due to high&#xD;
      variability of patient status, physiology, and compliance.&#xD;
&#xD;
      This is a prospective, single-center, observational open-label study. The primary objective&#xD;
      is to quantify changes to plasma volume and red blood cell volume over a 12 week period&#xD;
      post-discharge.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantify volume shifts in post discharge heart failure patients</measure>
    <time_frame>12 weeks</time_frame>
    <description>Accurately quantify changes to plasma volume and red blood cell volume in HF outpatients over the 12-week period following discharge.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Outpatients following discharge for treatment of heart failure</arm_group_label>
    <description>Daxor Corporation's commercially available Blood Volume Analyzer, BVA-100, will be performed at 5 timepoints for each patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BVA-100</intervention_name>
    <description>The BVA-100 is a software package designed to calculate human blood volume using the method of tracer dilution. It uses tagged serum albumin (a commonly used tag is 131I, resulting in &quot;131I -HSA&quot;). Data inputs to the software come from the measured characteristics of subject blood samples (hematocrit and tracer concentration) and tracer calibration standards. The package also calculates the subject expected (or ideal) blood volume from physical parameters. Hyper- or hypovolemia, associated red blood cell volumes, and transudation rate are reported, with statistics showing the quality of the results. The subject blood samples and calibration standards are measured in a gamma counter, whose output is automatically, or manually, input to this calculation program.</description>
    <arm_group_label>Outpatients following discharge for treatment of heart failure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All adult patients admitted to Geisinger Medical Center with a diagnosis of acute heart&#xD;
        failure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized male and female patients with primary or secondary admission diagnosis of&#xD;
             acute heart failure exacerbation&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  Able and willing to provide consent&#xD;
&#xD;
          -  Reduced or preserved LVEF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with current acute strokes&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Severe hypotension requiring resuscitation, intubation or circulatory support&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Patients with known cardiac amyloid and hypotension&#xD;
&#xD;
          -  Known allergy to iodine or iodinated albumin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Plasma Volume</keyword>
  <keyword>Red Blood Cell Volume</keyword>
  <keyword>Blood Volume</keyword>
  <keyword>Diuresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

